Journal
JAC-antimicrobial resistance
ISSN: 2632-1823
Titre abrégé: JAC Antimicrob Resist
Pays: England
ID NLM: 101765283
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
29
01
2021
accepted:
14
05
2021
entrez:
5
7
2021
pubmed:
6
7
2021
medline:
6
7
2021
Statut:
epublish
Résumé
Over recent years, France has experienced an increase of infections caused by carbapenem-resistant Gram-negative (GN) pathogens. Cefiderocol is approved in Europe for the treatment of aerobic GN infections in adults with limited treatment options. This study evaluated the MICs were determined by broth microdilution, according to International Organization for Standardization guidelines. Cefiderocol was tested using iron-depleted CAMHB. Susceptibility rates were based on EUCAST breakpoints. In the absence of a species-specific breakpoint, pharmacokinetic/pharmacodynamic breakpoints were used. Of 2027 isolates, 1344 (66.3%) were Enterobacterales and 683 (33.7%) were non-fermenters. The most common pathogen was Cefiderocol demonstrated high
Identifiants
pubmed: 34223140
doi: 10.1093/jacamr/dlab081
pii: dlab081
pmc: PMC8251251
doi:
Types de publication
Journal Article
Langues
eng
Pagination
dlab081Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
Références
J Antimicrob Chemother. 2018 Nov 1;73(11):3049-3052
pubmed: 30188999
Front Microbiol. 2019 Jan 30;10:80
pubmed: 30761114
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28630181
Int J Antimicrob Agents. 2019 Feb;53(2):177-184
pubmed: 30395986
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7396-7401
pubmed: 27736756
Euro Surveill. 2019 Feb;24(9):
pubmed: 30862330
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3163-9
pubmed: 26926648
Lancet Infect Dis. 2019 Jan;19(1):56-66
pubmed: 30409683
Eur J Clin Pharmacol. 2015 Jul;71(7):801-10
pubmed: 26008213
J Hosp Infect. 2009 Dec;73(4):338-44
pubmed: 19699552
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29061741
mSphere. 2019 Mar 27;4(2):
pubmed: 30918055
Med Mal Infect. 2020 Nov;50(8):715-722
pubmed: 32113869
JAC Antimicrob Resist. 2020 Aug 25;2(3):dlaa060
pubmed: 34223017
J Antimicrob Chemother. 2016 Mar;71(3):670-7
pubmed: 26645269
Antimicrob Agents Chemother. 2018 Jan 25;62(2):
pubmed: 29158270
Antimicrob Agents Chemother. 2016 Jun 20;60(7):4384-6
pubmed: 27139465
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S521-S528
pubmed: 31724045
J Antimicrob Chemother. 2020 Mar 1;75(3):769-771
pubmed: 31848599
Int J Antimicrob Agents. 2019 Apr;53(4):456-466
pubmed: 30471402
Antimicrob Agents Chemother. 2018 Dec 21;63(1):
pubmed: 30323035
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4490-500
pubmed: 27161636
Korean J Intern Med. 2012 Jun;27(2):128-42
pubmed: 22707882
Front Microbiol. 2014 Nov 26;5:643
pubmed: 25505462
Antimicrob Agents Chemother. 2015 Nov 16;60(2):729-34
pubmed: 26574013
Antimicrob Agents Chemother. 2007 Dec;51(12):4486-8
pubmed: 17938180
Clin Microbiol Rev. 2012 Jan;25(1):2-41
pubmed: 22232370
Chest. 2009 Nov;136(5):1237-1248
pubmed: 19696123
J Antimicrob Chemother. 2019 Aug 1;74(8):2239-2246
pubmed: 31127297
Open Forum Infect Dis. 2015 May 05;2(2):ofv050
pubmed: 26125030